CKCemşit Karakurt

Cemşit Karakurt

*This is an algorithmically generated author record based on publicly available information.

Cemşit Karakurt has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • The effects of therapeutic play on angiography procedures in children: a randomised controlled trial

    by Yeliz Suna Dağ, Emriye Hilal Yayan, Ezel Akçin, Özlem Elkiran, Cemşit Karakurt

    Objective: This study investigated the effects of therapeutic play on angiography in children aged 4–10. Methods: Our study was conducted as a randomised controlled experimental trial with 70 (experimental: 35, control: 35) children undergoing angiography at the paediatric cardiology clinic of a university hospital between 1 January 2022 and 31 August 2022. The “Child Information Form”, “Wong-Baker Faces Pain Rating Scale”, “Children’s Fear Scale”, “Children’s Anxiety Meter-State” and “Doll Model” were used for data collection. Percentage, mean, pearson correlation, ANOVA were used in the evaluation of the data. Results: It was found that 57.1% of the children who participated in our study were female, their mean age was 6.48±2.36 years, 45.7% had the diagnosis of Atrial Septal Defect (ASD), 78.6% had not undergone any surgery before and 60% were hospitalised for follow-up. It was found that the difference between pain, fear and anxiety scores of the children after the therapeutic play programme was statistically significant (p ˂ 0.05). Conclusions: Our study found that therapeutic play programmes can reduce pain, fear and anxiety in children. These findings demonstrate that negative experiences during invasive procedures affect children not only physiologically, but also psychologically and behaviourally. Therapeutic play can therefore be a powerful supportive intervention. Therefore, we recommend integrating therapeutic play into nursing clinical guidelines and care protocols, and providing paediatric nurses with training in this area.

  • Open Access

    Maternal Micronutrient Levels, Environmental Factors, and Their Association with Congenital Heart Disease and Extracardiac Anomalies in Infants: A Retrospective Analysis

    by Yurday Öncül, Gülendam Koçak, Cemşit Karakurt, Mehmet Çağatay Taşkapan

    Objectives: Congenital heart defects (CHDs) are among the most common congenital anomalies in newborns and frequently coexist with extracardiac malformations. Both genetic and environmental contributors have been implicated in CHD development, yet the influence of maternal micronutrient status and parental lifestyle factors remains insufficiently explored. This study aimed to evaluate maternal serum trace elements and vitamin levels in infants with CHD and/or extracardiac anomalies, and to identify potentially preventable maternal and paternal factors associated with these anomalies. Methodology: A retrospective study was conducted in a tertiary pediatric center in Turkey, including infants aged 0–3 months with CHD or extracardiac anomalies and their mothers. Healthy infants and their mothers served as controls. Maternal serum levels of magnesium, zinc, copper, vitamin A, vitamin E, vitamin B12, folic acid, and homocysteine were measured. Demographic, obstetric, lifestyle, and environmental variables were also recorded. Statistical comparisons were performed using t-tests, Mann–Whitney U tests, and chi-square tests (p<0.05). Results: Of 147 infants, 56 had CHD and 19 (33.9%) had CHD with extracardiac anomalies. Gastrointestinal (47.4%) and CNS anomalies (36.8%) were the most common associated defects. Mothers of CHD infants had significantly lower zinc [p=0.008] and vitamin A levels [p=0.001] and higher homocysteine levels [p=0.008] than controls. Paternal smoking was more frequent in the CHD group [p=0.008], while maternal literacy and adequate antenatal monitoring were significantly lower. No differences were found in maternal magnesium, copper, vitamin B12, folate, or vitamin E levels. Conclusion: Low maternal zinc and vitamin A levels, high homocysteine, and paternal smoking were associated with CHD in infants. As these factors are modifiable, they highlight opportunities for preventive strategies in maternal–child health. Further prospective studies are needed to clarify causality.

  • PLASMA CARDIAC MYOSIN BINDING PROTEIN C AND SERUM NT PRO BNP LEVELS IN CHILDREN WITH CONGESTIVE HEART FAILURE

    by Damla Erden, Cemşi̇t Karakurt, Mehmet Taşkapan, Özlem Elkiran, Hari̇kA Gözde Gözükara Bağ

    Çocuklarda kalp yetmezliği (KY), kalbin vücudun metabolik ihtiyaçlarını karşılayamaması olarak tanımlanan klinik bir sendromdur. Natriüretik peptitler ve kardiyak troponinler, KY’ nin tanısı ve prognozu için en çok kullanılan kardiyovasküler biyobelirteçlerdir. KY’ de tanı, prognoz ve risk sınıflandırmasıyla ilgili birçok başka biyobelirteç de tanımlanmıştır. Bu çalışmada, kardiyak miyozin bağlayıcı protein-C’ nin (cMyBP-C) prognostik değerinin, klinisyen tarafından çocuklarda yeni teşhis edilen KY’ yi değerlendirirken kullanılabilecek olası yeni bir biyobelirteç olup olmadığını araştırmayı amaçladık. Bu, konjestif kalp yetmezliği (KKY) olan 24 çocuk ve 30 sağlıklı çocuğu içeren prospektif bir vaka kontrol çalışmasıdır. Tıbbi öykü ve fizik muayene alındıktan sonra hastalar elektrokardiyografi, telekardiyografi ve ekokardiyografi ile değerlendirildi ve modifiye edilmiş bir Ross skorlaması yapıldı. Plazma cMyBP-C ve diğer biyobelirteç N-terminal pro-natriüretik peptid (NT-proBNP) değerleri, rutin kan testleri, karaciğer enzimleri başvuru sırasında ölçüldü. Hasta grubunun ortalama cMyBP-C (ng/ml) plazma düzeyi 1.55 ng/ ml (0.1-9.4), kontrol grubunun ise 0.1 ng/ml (0.3-1) idi (p<0.01). Etiyolojik araştırmanın değerlendirilmesi sonrasında miyokardit grubunda saptanan ortalama plazma cMyBP-C düzeyi 1.9 ng/ml (0.1-3.1) idi. Buna göre hasta grubunda cMyBP-C’nin ortalama değeri kontrol grubundan anlamlı olarak yüksek olup akut miyokardit grubunda en yüksekti (p<0.01). CMyBP-C, akut KY’ li çocuklarda yeni ve yararlı bir tanı ve prognoz biyobelirteci olabilir.

  • Effect of Piracetam and Iron Treatment on Heart Rate Variability in Patients With Breath-Holding Spell

    by Mehmet Öncül, Özlem Elkıran, Cemşit Karakurt, Serdal Güngör, Serdar Akın Maraş, Harika Gözde Gözükara Bağ


  • Combined (dual) drug therapy for the treatment of patent ductus arteriosus: last approach prior to ligation

    by Mehmet F. Deveci, Huseyin Kaya, Sadik Yurttutan, Meral Alagoz, Ismail K. Gokce, Cemsit Karakurt, Ufuk U. Gullu, Mehmet Oncul, Ramazan Ozdemir

    Objective: We aimed to evaluate the efficacy of combined (ibuprofen+paracetamol) medical therapy in cases of persistent haemodynamically significant patent ductus arteriosus that are resistant to standard medical monotherapy (ibuprofen and/or paracetamol) in this retrospective multi-centre study.Methods: The combined therapy included the administration of 15mg/kg/dose of paracetamol every 6 h for 3 days and ibuprofen at an initial dose of 10mg/kg/dose followed by 5 mg/kg/dose every 24 h. After 2 days following the administration of the last dose, the researchers evaluated the efficacy of combined treatment by conducting an echocardiographic examination.Results: Of all 42 patients who received combined therapy, 37 (88.1%) patients exhibited closure of the haemodynamically significant patent ductus arteriosus without requiring surgical ligation. Patients who did not respond to combined therapy had a higher mean birth weight and gestational age compared to those who responded (p < 0.05).Conclusion: The researchers believe the success of ibuprofen and paracetamol in haemodynamically significant patent ductus arteriosus treatment may be due to their synergistic efficacy and inhibition of the prostaglandin synthesis pathway through different enzymes. The results of our retrospective trial suggest that combination therapy with paracetamol and ibuprofen can be attempted when monotherapy is unsuccessful in treating haemodynamically significant patent ductus arteriosus, especially in centres without a surgical department.


  • Open Access

    Spontaneous Coronary Artery Dissection in Children with Duchenne Muscular Dystrophy

    by Mehmet Oncul, Cemsit Karakurt, Ozlem Elkiran, Siho Hidayet, Serdar Akin Maras

  • Open Access

    Congenital Heart Disease and COVID-19: A Single-Center Experience

    by Mehmet Öncül, Cemşit Karakurt, Özlem Elkıran, Harika Gözde Gözükara Bağ

    Background: Coronavirus disease 2019 (COVID-19) has been infecting children since December 2019 and has caused a severe epidemic and millions of deaths worldwide. COVID-19 has severe clinical effects and is more complicated to manage in patients with underlying diseases, such as congenital heart disease (CHD), past surgical operations, arrhythmia, and end-organ damage. Objectives: This study aimed to evaluate the clinical course, follow-up, and treatment process of patients with CHD and COVID-19 in Inonu University Faculty of Medicine, Department of Pediatrics, Turkey during March 2020-February 2021. Methods: This retrospective study was performed on patients with CHD and COVID-19 in the Department of Pediatrics at Inonu University Faculty of Medicine during March 2020-February 2021, selected by making full count sampling. Admission complaints, clinical findings, biochemical parameters, echocardiography results, hospitalization times, treatments, and clinical follow-up findings were retrieved from patients' files. Results: 11 patients with underlying CHD and COVID-19 were evaluated retrospectively during the study. Ten patients were hospitalized and treated due to COVID-19. Treatment of seven of these patients continued in the intensive care unit (ICU), and five were followed up under a mechanical ventilator. Two patients died during follow-up in the ICU. Conclusions: The clinical course of COVID-19 is severe, and the mortality rate is high in patients with serious diseases, such as underlying CHD. Therefore, COVID-19 in patients with CHD requires more serious and careful follow-up.

  • Severe portal hypertension due to congenital hepatoportal arteriovenous fistula associated with intrahepatic portal vein aneurysm

    by Buket Altuntaş, Ayşe Erden, Cemşit Karakurt, Altuğ Kut, Nesrin Şenbil, Mehmet Yurdakul

    A 13‐year‐old girl was referred for assessment of severe gastrointestinal tract bleeding. Her liver function tests were normal, and she had no evidence of chronic liver disease or history of significant trauma. Clinical and sonographic findings suggested the presence of a portal vein aneurysm associated with a hepatoportal arteriovenous fistula. Abdominal angiography confirmed the diagnosis. The arteriovenous fistula was congenital, and the associated portal vein aneurysm was either congenital or secondary to hemodynamic changes in the portal venous system. © 1998 John Wiley & Sons, Inc. J Clin Ultrasound 26:357–360, 1998.